News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,985 Results
Type
Article (41351)
Company Profile (266)
Press Release (688351)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204848)
Career Advice (2031)
Deals (35579)
Drug Delivery (128)
Drug Development (81505)
Employer Resources (173)
FDA (16502)
Job Trends (14982)
News (346811)
Policy (32751)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2594)
Accelerated approval (45)
Adcomms (26)
Allergies (170)
Alliances (49581)
ALS (207)
Alzheimer's disease (1779)
Antibody-drug conjugate (ADC) (436)
Approvals (16874)
Artificial intelligence (649)
Autoimmune disease (277)
Automation (54)
Bankruptcy (362)
Best Places to Work (11639)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (176)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (742)
Cancer (5742)
Cardiovascular disease (465)
Career advice (1723)
Career pathing (41)
CAR-T (323)
CDC (56)
Celiac Disease (3)
Cell therapy (875)
Cervical cancer (46)
Clinical research (70710)
Collaboration (2026)
Company closure (5)
Compensation (1379)
Complete response letters (78)
COVID-19 (2740)
CRISPR (107)
C-suite (1099)
Cystic fibrosis (150)
Data (7713)
Decentralized trials (3)
Denatured (27)
Depression (158)
Dermatology (83)
Diabetes (582)
Diagnostics (6912)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (313)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91824)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119280)
Executive appointments (1074)
FDA (20179)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1700)
Gene editing (231)
Generative AI (55)
Gene therapy (705)
GLP-1 (1048)
Government (4726)
Grass and pollen (6)
Guidances (408)
Healthcare (18982)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (284)
Immuno-oncology (90)
Indications (187)
Infectious disease (3076)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16666)
IRA (50)
Job creations (3647)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (561)
Leadership (38)
Legal (7954)
Liver cancer (99)
Longevity (32)
Lung cancer (755)
Lymphoma (425)
Machine learning (59)
Management (59)
Manufacturing (1023)
MASH (183)
Medical device (13917)
Medtech (14028)
Mergers & acquisitions (20150)
Metabolic disorders (1480)
mRNA (199)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (407)
Neuropsychiatric disorders (104)
Neuroscience (3268)
Neurotech (1)
NextGen: Class of 2026 (6522)
Non-profit (4530)
Now hiring (77)
Obesity (693)
Opinion (285)
Ovarian cancer (217)
Pain (250)
Pancreatic cancer (294)
Parkinson's disease (355)
Partnered (33)
Patents (590)
Patient recruitment (660)
Peanut (62)
People (59539)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22039)
Phase 2 (31153)
Phase 3 (23183)
Pipeline (8343)
Policy (312)
Postmarket research (2568)
Preclinical (9380)
Press Release (64)
Prostate cancer (292)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1055)
Real estate (5969)
Recruiting (70)
Regulatory (25341)
Reports (56)
Research institute (2413)
Resumes & cover letters (353)
Rett syndrome (36)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (286)
Series B (210)
Service/supplier (11)
Sickle cell disease (110)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (48)
Startups (3639)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1086)
Venture capital (107)
Weight loss (444)
Women's health (123)
Worklife (20)
Date
Today (138)
Last 7 days (921)
Last 30 days (3203)
Last 365 days (30190)
2026 (11689)
2025 (30170)
2024 (35213)
2023 (40073)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46540)
2018 (35023)
2017 (32113)
2016 (31490)
2015 (37557)
2014 (31319)
2013 (26346)
2012 (28571)
2011 (29264)
2010 (27329)
Location
Africa (741)
Alabama (91)
Alaska (7)
Arizona (346)
Arkansas (14)
Asia (39636)
Australia (6500)
California (13075)
Canada (3716)
China (1318)
Colorado (559)
Connecticut (568)
Delaware (398)
Europe (85747)
Florida (1956)
Georgia (420)
Hawaii (3)
Idaho (62)
Illinois (1042)
India (88)
Indiana (594)
Iowa (23)
Japan (526)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1570)
Massachusetts (9322)
Michigan (358)
Minnesota (706)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3443)
New Mexico (29)
New York (3414)
North Carolina (1657)
North Dakota (9)
Northern California (6538)
Ohio (391)
Oklahoma (23)
Oregon (41)
Pennsylvania (2631)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5158)
Tennessee (209)
Texas (2070)
United States (46126)
Utah (391)
Vermont (1)
Virginia (313)
Washington D.C. (80)
Washington State (1047)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
729,985 Results for "23andme inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Regeneron Comes to 23andMe’s Rescue With $256M Acquisition Plan
Regeneron promised to comply with 23andMe’s consumer privacy policies and related data security laws.
May 19, 2025
·
2 min read
·
Tristan Manalac
Press Releases
23andMe Introduces Reconstructed Ancestors a First-of-Its-Kind DNA Discovery Tool
March 13, 2026
·
4 min read
Press Releases
New 23andMe Research Institute Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects
April 8, 2026
·
4 min read
Mergers & acquisitions
Regeneron Backs Off 23andMe, Losing Bid to Former CEO
Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” according to a spokesperson for the pharma.
June 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
23andMe Research Institute Appoints Privacy Advisory Board
October 31, 2025
·
3 min read
Press Releases
23andMe Research Institute Appoints John McLeod General Counsel and Chief Risk Officer
December 10, 2025
·
2 min read
Press Releases
23andMe Research Institute Appoints Kael Reicin as Chief Financial Officer
November 6, 2025
·
2 min read
Layoffs
23andMe Cuts Headcount by 40%, Drops Drug Discovery Work
In line with the restructuring initiative, 23andMe is looking for strategic opportunities for its pipeline assets, including licensing deals or outright sales.
November 12, 2024
·
2 min read
·
Tristan Manalac
Press Releases
23andMe Research Institute Names Brad Margus and Stephen Quake, D.Phil., to Board of Directors
October 27, 2025
·
3 min read
Press Releases
23andMe Research Institute Helps Reconnect African Diaspora to Their Roots with Release of 250+ High-Resolution African Genetic Groups
November 21, 2025
·
4 min read
1 of 72,999
Next
